Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

Core Insights - Labcorp Holdings, Inc. has launched the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based in-vitro diagnostic test for Alzheimer's disease [1][9] - The new test replaces a previous version introduced in April 2025, enhancing the diagnostic process for Alzheimer's [2] - The test offers a less invasive and more affordable alternative to traditional diagnostic methods like cerebrospinal fluid testing and PET scans [5][9] Company Performance - Following the announcement, Labcorp's stock increased by 0.04%, closing at $270.49, indicating positive market sentiment [3] - Labcorp has a market capitalization of $22.47 billion, with earnings expected to grow by 11.9% in 2025 and revenues by 7.7% [4] - Over the past year, Labcorp shares have risen by 19.8%, outperforming the industry average of 18.3% [12] Product Details - The Lumipulse test is designed for adults aged 50 and older showing cognitive decline symptoms and is not a standalone diagnostic test [7] - Clinical studies reported a positive predictive value of 92% and a negative predictive value of 97% for the new test [5] - The launch aligns with new clinical guidelines from the Alzheimer's Association, promoting the use of blood-based biomarkers in Alzheimer's evaluation [6][9] Industry Outlook - The global Alzheimer's disease diagnostics market was valued at $8.33 billion in 2024 and is projected to grow at a compound annual growth rate of 11% through 2030 [10] - Key growth factors include the increasing prevalence of Alzheimer's disease, the adoption of personalized products, and advancements in medical imaging technology [10] Additional Developments - Labcorp recently launched Test Finder, a generative AI tool to simplify lab test selection for healthcare providers [11]